Please ensure Javascript is enabled for purposes of website accessibility

Seattle Genetics Reports Q4 Earnings Results

By Mark Prvulovic - Feb 6, 2020 at 6:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company beat analyst estimates handily as revenues from royalties, license agreements, and Adcentris sales surged.

Seattle Genetics (SGEN -0.95%) reported its fourth-quarter and 2019 full-year financial results this afternoon. Revenue for Q4 came in at $289.8 million, a substantial increase from the $174.5 million reported for Q4 2018. While net product sales have gone up noticeably, royalty and license agreements revenues have seen exponential growth as well, with both having almost tripled over the past 12 months.

The bulk of the quarter's revenue came from sales of Adcentris, a cancer drug used to treat patients with Hodgkin lymphoma. The drug brought in $166.2 million in sales in the U.S. and Canada, a 26% increase from the $132.1 million reported in Q4 2018. 

Abstract picture of a pipette dripping liquid into a test tube.

Image source: Getty Images.

Overall, this handily beat Wall Street's estimates for the quarter, with the consensus sales forecast predicting around $219.2 million in revenue. For 2020, Seattle Genetics expects between $675 million to $700 million in Adcentris sales, $105 million to $115 million in royalty revenue, and another $30 million to $50 million in income from license agreements.

A strong ending to a strong year

Seattle Genetics has been one of the top-performing biotech stocks of last year, with shares having shot up by 102% in 2019. In December, the company submitted a New Drug Application (NDA) for a new HER-2 positive breast cancer drug known as tucatinib. The drug had already received breakthrough designation from the Food and Drug Administration (FDA) in December.

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Seattle Genetics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seagen Inc. Stock Quote
Seagen Inc.
$168.53 (-0.95%) $-1.61

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.